News from soligenix, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 03, 2015, 07:00 ET

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Feb 13, 2015, 07:00 ET

Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Feb 11, 2015, 07:00 ET

Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Feb 05, 2015, 07:00 ET

Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address...

Feb 02, 2015, 07:00 ET

Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Jan 29, 2015, 07:00 ET

Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Jan 07, 2015, 07:00 ET

FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Jan 05, 2015, 07:00 ET

Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Dec 29, 2014, 07:00 ET

Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Dec 24, 2014, 09:23 ET

Soligenix Announces Closing of Public Offering of Units

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Dec 19, 2014, 08:24 ET

Soligenix Announces Pricing of Public Offering of Units

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Dec 11, 2014, 07:00 ET

Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Dec 10, 2014, 07:00 ET

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Nov 17, 2014, 07:15 ET

Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Nov 10, 2014, 07:00 ET

Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 23, 2014, 07:00 ET

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 19, 2014, 07:00 ET

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Sep 17, 2014, 07:00 ET

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 09, 2014, 07:00 ET

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Sep 08, 2014, 07:00 ET

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...